Last reviewed · How we verify

NCT07065214: OVAPLAS

Argon Plasma Treatment for Ovarian Endometrioma Compared to Standard Cystectomy

Recruiting now NA Last updated 28 November 2025
What this trial tests

NA trial testing APC in Endometriosis in 72 participants. Currently enrolling.

Timeline
26 November 2025
Primary endpoint
1 March 2027
30 September 2027

Quick facts

Lead sponsorErbe Elektromedizin GmbH
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment72
Start date26 November 2025
Primary completion1 March 2027
Estimated completion30 September 2027
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Erbe Elektromedizin GmbH — full company profile →

Who can join

Adults 18 to 40, female only, with Endometriosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a prospective, monocentric, randomized controlled, two-armed, pilot-study conducted at Department for Women's Health, Tuebingen, Germany. In this Post Market Study it will be determined whether and to what extent the two surgical procedures for ovarian endometrioma treatment (standard cystectomy versus APC) may affect the ovarian reserve by comparing changes in serum AMH levels after treatment. Seventy-two (72) patients who meet all eligibility criteria will undergo surgical procedure. The patients will be randomized into the group with standard cystectomy treatment or with APC treatment. Per group n=36 patients will be treated i.e., 1:1 randomization. A pre-specified primary endpoint analysis is planned after the last patient has undergo Visit 4 (Follow-up after 6 months) to analyze the primary endpoint. Screening takes place during the first visit (V1). During the second visit (V2) the participants will receive the ovarian endometriosis treatment procedure either with the APC or the standard cystectomy. Standard procedure (standard cystectomy) will be performed for additional endometriosis lesions. The follow up visits (V3 - V5) will take place after three, six and twelve months. Visit 3 and Visit 4 will take place at the study site and AMH will be measured. Whereas Visit 5 will take place via telemedical contact, i.e. phone call.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Endometriosis

Currently open trials in the same condition.

Other Erbe Elektromedizin GmbH trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07065214.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing